Journal ArticleOPEN ACCESS

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

  • San Miguel J
  • Schlag R
  • Khuageva N
  • et al.
New England Journal of Medicine (2008) 359(9) 906-917
DOI: 10.1056/nejmoa0801479
1.7kCitations
Citations of this article
682Readers
Mendeley users who have this article in their library.

Abstract

The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone. This phase 3 study compared the use of melphalan and prednisone with or without bortezomib in previously untreated patients with multiple myeloma who were ineligible for high-dose therapy.

Cite

CITATION STYLE

APA

San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., … Richardson, P. G. (2008). Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. New England Journal of Medicine, 359(9), 906–917. https://doi.org/10.1056/nejmoa0801479

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free